APPLICANT'S

Attorney Docket: 92114.005US1	Senal Noc	
Applicant: Haim Danenberg		
Filing Date: 06/27/03	Group Art 1	Init: 1614

INFORMATION DISCLOSURE CITATION (Substitute Form PTO-1449B) NON PATENT LITERATURE DOCUMENTS include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title Examiner Cite of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue initials No. number(s), publisher, city and/or country where published. Translation Van Leut, et al., "In Vivo Role of Phagocytic Synovial Lining Cells in Onset of □ Yes □ No 1 Experimental Arthritis," Am. J. Pathol., 143:1226-37 (1993). ☐ Abstract 🔯 N/A Rogers, et al., "Morocyte Recruitment and Neointimal Hyperplasia in Rabbits." ☐ Yes ☐ No 2 Arteriosclerosis, Thrombosis, and Vascular Biology, 16:1312-18 (1996). Abstract @ N/A 3. Kumiomo, et al., Abstraci, "Experimental Induction of Athero Sclerosis in Guinea-☐ Yes ☐ No Pigs Fed a Cholesterol Vitamin D-2-Rich Diet" (1983). Abstract □ N/A Gennaro, "Parenteral Preparations," Remington: The Science and Practice of 4. ☐ Yes ☐ No. Pharmacy, 20th Ed., Ch. 41, pp. 780-920. 🔲 Abstract 🔯 N/A Fleisch, "Bisphosphonates in bone disease," Parthenon Publishing Group Inc., pp. 5. ☐ Yes ☐ No 184-210 (1997). C Abetiso D N/A Mak, et al., "Clinical Trials to prevent Restenosis after Percutaneous Coronary 8. ☐ Yes ☐ No. Revuscularization," The NY Academy of Sciences, pp. 225-77 (1994). Abstract NA Leclerc, et al., "Drug prevention of restenosis after angioplasty: an update," Elsevier 7, ☐ Yes ☐ No Science, pp. 722-24 (1995). O Abstraci 🖾 N/A Lefkovits, et al., "Pharmacological Approaches for the Prevention of Restenosis 81 ☐ Yes ☐ No. After Percutaneous Coronary Intervention," Progress in Cardiovascular Disease, ☐ Abstract ※ N/A 40(2):141-58 (1997). Hamon, et al., "Restenosis after coronary angioplasty," Eur. Heart J., 16:33-48 DYE DNO Abstract N/A Gottsauner-Wolf, et al., "Influence of local delivery of the protein tyrosine kinase 10. ☐ Yes ☐ No. receptor inhibitor tyrphostin-47 on smooth-muscle cell proliferation in a rat carotid CJ Abstract 🗵 N/A balloon-injury model," Am. Heart J., 19:347-56 (1996). Shioi, et al., "B-Glycerophosphate Accelerates Calcification in Cultured Bovine 11. ☐ Yes ☐ Mo Vascular Smooth Muscle Cells," Arteriosclerosis, Thrombosis and Vascular ☐ Abstract 図 N/A Biology, 15(11):2003-9 (1995). Bellah, et al., "Idiopathic arterial calcification of infancy: Prenatal and postnatal 32. ☐ Yes ☐ No effects of therapy in an infant," The Journal of Pediatrics, 121(6):930-3 (1992). Abstract N/A Waller, et al., "Coronary Artery and Saphenous Vein Graft Remodeling: A Review 13. T Yes T No. of Histologic Findings after Various Interventional Procedure - Part VL" Clin. 🔲 Alestraci 🖾 N/A Cardiol., 20:153-60 (1997). 14. Anderson, ci al., "A review of randomized trials comparing coronary angioplasty ☐ Yes ☐ No and bypass grafting," Curr-Opin-Cardiol., 11(6):583-90 (1996). Abstract N/A Moorman, et al., "Percutaneous Transluminal Coronary Angioplasty (PTCA): Long-15. ☐ Yes ☐ No term Outcome and Aeromedical Implications," Aviation, Space and Environmental C Abamid 2 N/A Medicine, 67(10):990-6 (1998). Laurent, et al., "The arterial wall: a new pharmacological and therapeutic target," 16 ☐ Yes ☐ No. Fundam, Clin. Pharmacol., 10:243-57 (1996). Abstract N/A 17. Schwartz, "The vessel wall reaction in restenosis," Semin. Intervent, Cardiol., 2:83-☐ Yes ☐ No 8 (1997). □ Abstract □ N/A Affaire, et al., "Endothelial Cell Injury in Cardiovascular Surgery: The Intimal IX. U Yes U No. Hyperplastic Response," Ann. Thorac. Surg., 63(2):582-91 (1997). Abstract NA

Serial No.: 10/607,623

Attorney Docket No.: 92114,005US1 Applicant: Haim Danenberg

19.	Webb, et al., "Inhibition of Bioprosthetic Heart Valve Calcification with Aminodiphosphonate Covalently Bound to Residual Aldehyde Groups," <i>Ann. Thorac. Surg.</i> , 46:309-16 (1988).	□ Yes □ No □ Absince ⊠ N/A
20.	Wagner, et al., "Contrasting Effects of Ethane-1-Hydroxy-1, 1-Diphosphonate (EHDP) on the Regression of two types of Dietary-Induced Atherosclerosis," Atherosclerosis, 27:419-35 (1977).	☐ Yes ☐ No ☐ Abelosed ❷ N/A
21.	Daoud, et al., "The effect of ethane-1-hydroxy-1, 1-diphosphonate (EHDP) on necrosis of atherosclerotic lesions," <i>Atheroscleroxis</i> , 67:41-8 (1987).	☐ Yes ☐ No ☐ Abstract ❷ N/A
22.	Walsh, et al., "Molecular strategies to inhibit restenosis: modulation of the vascular myocyte phenotype," Semin. Intervent. Cardiol., 1:173-9 (1996).	O Yes O No O Abstract & N/A
23.	Herrman, et al., "Pharmacological Approaches to the Prevention of Restenosis Following Angioplasty," <i>Drugs</i> , 46(1):18-52 (1993).	O Yes O No O Abstract Ø N/A
24.	Rubin, et al., "Cellular and Molecular Mechanisms of Radiation Inhibition of Restenosis. Part I: Role of the Macrophage and Platelet-Derived Growth Factor," Int. J. Radiation Oncology Biol. Phys., 40:929-41 (1998).	☐ Yes ☐ No ☐ Abstract ❷ N/X
25.	Makkar, et al., "Prevention of Restenosis by Local Drug Delivery," J. Cardiovasc. Pharmacol, Therapeut., 1(2):177-88 (1996).	O Yes O No O Abelinia (8) N/A
26.	Areficva, ci al., "Monocyte Integrin Expression and Monocyte-Platelet Complex Formation in Humans with Coronary Restenosis," <i>Clin. Exp. Pharm. Physio.</i> , 28:804-8 (2001).	□ Yeş □ No □ Abstract ⊠ N/A
27.	Bohm, et al., "Exogenous Hepatitis B Surface Antigen Particles Processed by Dendritic Cells or Macrophages Prime Murine MHC Class I-Restricted Cytotoxic T Lymphocytes In Vivo," J. Immunol., 155:3313-21 (1995).	☐ Yes ☐ No ☐ Abstract ☒ N/A
28.	Buiting, et al., "Liposomes as antigen carriers and adjuvants in vivo," Res. Immunol., 143:541-8 (1992).	☐ Yes ☐ No ☐ Abstract ❷ N/A
29	Bergh, et al., "Liposome-mediated macrophage depletion: an experimental approach to study the role of testicular macrophages in the rat," <i>J. Endocrinol.</i> , 136:407-13 (1993).	□ Yes □ No □ Abstinca 図 N/A
30.	Van Rooijen, et al., "Apoptosis of macrophages induced by liposome-mediated intracellular delivery of elodronate and propamidine," <i>J. Immunol. Methods</i> , 193:93-9 (1996).	□ Yes □ Ne □ Absumet 図 N/A
31.	Lecnaars, et al., "Increased adjuvant efficacy in stimulation of antibody responses after macrophage climination in vivo," Immunol., 90:337-43 (1997).	☐ Yes ☐ No ☐ Abstract ※ N/A
32.	Yue, et al., "In Vivo Myocardial Protection From Ischemia/Reperfusion Injury by the Peroxisome Proliferator-Activated Receptor-y Agonist Rosiglitazone," Circulation, 104:2588-94 (2001).	□ Yes □ Ne □ Abstract ❷ N/A
33.	Bolli, et al., "Evidence That Late Preconditioning Against Myocardial Stunning in Conscious Rabbits Is Triggered by the Generation of Nitric Oxide," Circulation Res., 81:42-52 (1997).	□ Yes □ No □ Abstract 図 N/A
34.	Zhao, et al., "Myocardial apoptosis and ischemic preconditioning," Cardiovase. Res., 55:438-55 (2002).	□ Yes □ No □ Abstract 図 N/A
35.	Van Rooijen, et al., "The macrophage as target or obstacle in liposome-based targeting strategies," Int. J. Pharmaceu., 162:45-50 (1998).	☐ Yes ☐ No ☐ Abstract ፟፟፟ N/A
36.	Matthews, et al., "Comparison of the response of primary human peripheral blood mononuclear phagocytes from different donors to challenge with model polyethylene particles of known size and dose," <i>Biomaterials</i> , 21:2033-44 (2000).	☐ Yes ☐ No ☐ Abstract ☑ N/A

Serial No.: 10/607,623

Attorney Docket No.: 92114.005US1 Applicant: Haim Danenberg

	37,	Fisher, ct al., "Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro," Cell Biol., 96:133-8 (1999).	☐ Yes ☐ No ☐ Absumet 🔯 N/A
	38.	Sansoni, et al., "Inhibition of antigen-presenting cell function by alendronate in vitro," J. Bone Min. Res., 10(11):1719-25 (1995).	☐ Yes ☐ No Ø Abstract ☐ N/A
	39.	Lodge-Paich, "The Ageing of Cardiac Infarcts, and its Influence on Cardiac Rupture," <i>Br. Heart J.</i> , pp. 37-42 (1951).	□ Ves □ №0 □ Abstract ◎ N/A
	40.	Jalowy, et al., "AT1 receptor blockade in experimental myocardial ischemia/reperfusion," Basic Res. Cardiol., 93(2):85-91 (1998).	O Yes O No O Absided Ø N/A
	41.	Response filed December 22, 2009 in related patent application 10/871,488 in response to October 29, 2009 Final Office Action.	☐ Yes ☐ No ☐ Abstissed ❷ N/A
	42.	Non-Final Office Action in related patent application 11/190,787 dated March 3, 2010.	□ Yes □ No □ Absimet 図 N/A
	43,	Response filed June 1, 2010 in related patent application 11/190,787 in response to March 3, 2010 Non-Final Office Action.	☐ Yes ☐ No ☐ Abstract ② N/A
S	·		
ixaniiner ignature	į	Date Considered	
EXAMINER:	1,	missi if reference considered, whether or not contion is in conformance with MPFF \$609. haw line through estation if not in conformance and not considered. schole copy of this form with next communication to amplicant.	